N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=9,902 A Study of S-268019 for the Prevention of COVID-19
SARS-CoV-2
Primary: Number of Participants With First Occurrence of SARS-CoV-2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Positive Symptomatic COVID-19 With Onset at Least 14…
Phase 4 N=50 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
Increased Risk of SARS-CoV-2 Infection
Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants
Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
Phase 2 N=98 COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
COVID-19 · SARS-CoV 2
Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers
N/A N=112 Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
COVID-19
Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale
Phase 2 N=256 Study of AZD1222 for the Prevention of COVID-19 in Japan
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
Phase 2 N=399 A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
COVID-19
Primary: COVID-19 Prophylaxis — 30; 105 Participants
N/A N=820 The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
Covid19
Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020
Phase 4 N=659 BCG Vaccine for Health Care Workers as Defense Against COVID 19
Coronavirus · Coronavirus Infection · Coronavirus as the Cause of Diseases Classified Elsewhere
Primary: Number of New COVID 19 Infections — 25; 21 Participants
N/A N=229 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Covid19
Primary: Number of Infected Subjects — 0; 11 Participants — p=< 0.0001
Phase 3 N=1,483 Pre-exposure Prophylaxis for SARS-Coronavirus-2
COVID-19 · Corona Virus Infection · ARDS
Primary: COVID-19-free Survival — 464; 468; 454 Participants
N/A N=9,374 Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings
Intellectual Disability · Developmental Disability · Axis I Diagnosis
Primary: New COVID-19 Group Home Incidence — 1.61; 1.40; 0.16; 0.09 New COVID-19 cases per 100 person-months — p=0.89
Phase 3 N=3,298 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Healthy Participants
Primary: Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP — 7.8; 1.4 Percentage of Participants…
Phase 3 N=2,834 Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs) in Primary Vaccination Cohort (PVC):- AZD2816 (4), Booster…
Phase 4 N=60 The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients
COVID-19
Primary: E Genes — 28.50; 27.33; 30.28; 27.80 Cycle
N/A N=100 APT™ T3X on the COVID-19 Contamination Rate
COVID-19
Primary: COVID-19 Contamination Rate. — 2; 5 Participants
Phase 1 N=185 Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
Phase 3 N=1,187 The Prevent Severe COVID-19 (PRESECO) Study
Covid19
Primary: Number of Participants With Sustained Clinical Recovery — 425; 475 Participants
N/A N=215 COVID-19 Risk Reduction Among African American Parishioners
Coronavirus
Primary: Mean Change in the Ability to Implement COVID-19 Health Guidelines Among African American Churches in South Los Angeles 3 Months After Workshop — 3.00000 score on a…
N/A N=74 Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
HIV-1-infection · Hypertension
Primary: Proportion of Eligible Participants Who Agree to Participate — 74 Participants
N/A N=630 Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
COVID-19 Respiratory Infection · Acute Respiratory Disease
Primary: The Proportion of Patients With Acute Respiratory Viral Infections, Including COVID-19, at the End of the Prophylactic Period — 3; 13 participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=3,632 Epidemiological Study of the COVID-2019 in Participating Organizations.
Covid19
Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person
Phase 3 N=2,441 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With…
Phase 2 N=221 Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
COVID-19
Primary: Number of Participants Infected With COVID-19 or COVID-19 Like Illness During the Trial — 13; 32 Participants — p=0.0112
Phase 1 N=99 Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Phase 3 N=5,197 Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
COVID-19
Primary: Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness — 8; 17; 12; 34 Participants — p=<0.001
Phase 1 N=48 Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19
SARS-CoV-2
Primary: The Number of Participants With Serious Adverse Events Following Administration of ADM03820 to the Final Visit — 1; 1; 0; 0 Participants
Phase 3 N=32 Early Treatment of Cytokine Storm Syndrome in Covid-19
Cytokine Storm · COVID-19
Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants